Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Literature DB >> 28640269

Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Jeff Sevigny, Ping Chiao, Thierry Bussière, Paul H Weinreb, Leslie Williams, Marcel Maier, Robert Dunstan, Stephen Salloway, Tianle Chen, Yan Ling, John O'Gorman, Fang Qian, Mahin Arastu, Mingwei Li, Sowmya Chollate, Melanie S Brennan, Omar Quintero-Monzon, Robert H Scannevin, H Moore Arnold, Thomas Engber, Kenneth Rhodes, James Ferrero, Yaming Hang, Alvydas Mikulskis, Jan Grimm, Christoph Hock, Roger M Nitsch, Alfred Sandrock.

Abstract

This corrects the article DOI: 10.1038/nature21361.

Entities: Chemical Disease

Year: 2017 PMID： 28640269 DOI： 10.1038/nature22809

Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962

1 in total

1. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Authors: Jeff Sevigny; Ping Chiao; Thierry Bussière; Paul H Weinreb; Leslie Williams; Marcel Maier; Robert Dunstan; Stephen Salloway; Tianle Chen; Yan Ling; John O'Gorman; Fang Qian; Mahin Arastu; Mingwei Li; Sowmya Chollate; Melanie S Brennan; Omar Quintero-Monzon; Robert H Scannevin; H Moore Arnold; Thomas Engber; Kenneth Rhodes; James Ferrero; Yaming Hang; Alvydas Mikulskis; Jan Grimm; Christoph Hock; Roger M Nitsch; Alfred Sandrock
Journal: Nature Date: 2016-09-01 Impact factor: 49.962

1 in total

20 in total

Review 1. The Lymphatic Vasculature in the 21^st Century: Novel Functional Roles in Homeostasis and Disease.

Authors: Guillermo Oliver; Jonathan Kipnis; Gwendalyn J Randolph; Natasha L Harvey
Journal: Cell Date: 2020-07-23 Impact factor: 41.582

2. Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease.

Authors: Crystal M Vander Zanden; Eva Y Chi
Journal: J Pharm Sci Date: 2019-10-21 Impact factor: 3.534

3. Exploiting the Full Potential of β-Amyloid and Tau PET Imaging for Drug Efficacy Testing.

Authors: Henryk Barthel; John Seibyl; Adriaan A Lammertsma; Victor L Villemagne; Osama Sabri
Journal: J Nucl Med Date: 2020-05-15 Impact factor: 10.057

4. β-amyloid and tau pathology in the aging feline brain.

Authors: Kimberly L Fiock; Jodi D Smith; John F Crary; Marco M Hefti
Journal: J Comp Neurol Date: 2019-07-12 Impact factor: 3.215

Review 5. Radioactive synthesis of tau PET imaging agent ¹⁸F-AV-1451 and its role in monitoring the progression of Alzheimer's disease and supporting differential diagnosis.

Authors: Wenyan Zhang; Shuoyan Xu; Hongmei Yu; Xuena Li; Zhuangzhuang Jin; Yaming Li; Zhiyi He
Journal: Ann Nucl Med Date: 2021-01-18 Impact factor: 2.668

6. Identifying candidate genes and drug targets for Alzheimer's disease by an integrative network approach using genetic and brain region-specific proteomic data.

Authors: Andi Liu; Astrid M Manuel; Yulin Dai; Brisa S Fernandes; Nitesh Enduru; Peilin Jia; Zhongming Zhao
Journal: Hum Mol Genet Date: 2022-09-29 Impact factor: 5.121

7. Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee.

Authors: Gregory S Day; Nikolaos Scarmeas; Richard Dubinsky; Katherine Coerver; Anitra Mostacero; Brooks West; Scott R Wessels; Melissa J Armstrong
Journal: Neurology Date: 2022-02-23 Impact factor: 11.800

8. Quantitative Susceptibility Mapping of Brain Iron and β-Amyloid in MRI and PET Relating to Cognitive Performance in Cognitively Normal Older Adults.

Authors: Lin Chen; Anja Soldan; Kenichi Oishi; Andreia Faria; Yuxin Zhu; Marilyn Albert; Peter C M van Zijl; Xu Li
Journal: Radiology Date: 2020-11-24 Impact factor: 11.105

Review 9. Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

Authors: Phuong H Nguyen; Ayyalusamy Ramamoorthy; Bikash R Sahoo; Jie Zheng; Peter Faller; John E Straub; Laura Dominguez; Joan-Emma Shea; Nikolay V Dokholyan; Alfonso De Simone; Buyong Ma; Ruth Nussinov; Saeed Najafi; Son Tung Ngo; Antoine Loquet; Mara Chiricotto; Pritam Ganguly; James McCarty; Mai Suan Li; Carol Hall; Yiming Wang; Yifat Miller; Simone Melchionna; Birgit Habenstein; Stepan Timr; Jiaxing Chen; Brianna Hnath; Birgit Strodel; Rakez Kayed; Sylvain Lesné; Guanghong Wei; Fabio Sterpone; Andrew J Doig; Philippe Derreumaux
Journal: Chem Rev Date: 2021-02-05 Impact factor: 60.622

10. Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers.

Authors: Rik Ossenkoppele; Juhan Reimand; Ruben Smith; Antoine Leuzy; Olof Strandberg; Sebastian Palmqvist; Erik Stomrud; Henrik Zetterberg; Philip Scheltens; Jeffrey L Dage; Femke Bouwman; Kaj Blennow; Niklas Mattsson-Carlgren; Shorena Janelidze; Oskar Hansson
Journal: EMBO Mol Med Date: 2021-07-13 Impact factor: 12.137

Review 1. The Lymphatic Vasculature in the 21st Century: Novel Functional Roles in Homeostasis and Disease.

Review 5. Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer's disease and supporting differential diagnosis.

Review 9. Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

Review 1. The Lymphatic Vasculature in the 21^st Century: Novel Functional Roles in Homeostasis and Disease.

Review 5. Radioactive synthesis of tau PET imaging agent ¹⁸F-AV-1451 and its role in monitoring the progression of Alzheimer's disease and supporting differential diagnosis.